Raytne

Raytne is a leading biopharmaceutical company focused on innovative ophthalmic drugs and medical devices with clinical advantages. The core technical team comes from the PLA General Hospital and the Academy of Military Medical Sciences. Raytne’s DNA combines financial thinking with industry logic. Its current R&D pipeline includes six new drugs and one Class III medical device, targeting indications such as myopia, viral keratitis, treatment and correction of presbyopia, macular degeneration, dry eye syndrome, and intraocular lenses.